Cargando…

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

Factors reflecting two major aspects of tumour biology, invasion (urokinase-type plasminogen activator (uPA), plasminogen activator inhibiter (PAI-1), cathepsin D) and proliferation (S-phase fraction (SPF), Ki-67, p53, HER-2/neu), were assessed in 125 node-negative breast cancer patients without adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Harbeck, N, Dettmar, P, Thomssen, C, Berger, U, Ulm, K, Kates, R, Höfler, H, Jänicke, F, Graeff, H, Schmitt, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362313/
https://www.ncbi.nlm.nih.gov/pubmed/10408848
http://dx.doi.org/10.1038/sj.bjc.6690373
_version_ 1782153426807816192
author Harbeck, N
Dettmar, P
Thomssen, C
Berger, U
Ulm, K
Kates, R
Höfler, H
Jänicke, F
Graeff, H
Schmitt, M
author_facet Harbeck, N
Dettmar, P
Thomssen, C
Berger, U
Ulm, K
Kates, R
Höfler, H
Jänicke, F
Graeff, H
Schmitt, M
author_sort Harbeck, N
collection PubMed
description Factors reflecting two major aspects of tumour biology, invasion (urokinase-type plasminogen activator (uPA), plasminogen activator inhibiter (PAI-1), cathepsin D) and proliferation (S-phase fraction (SPF), Ki-67, p53, HER-2/neu), were assessed in 125 node-negative breast cancer patients without adjuvant systemic therapy. Median follow-up time was 76 months. Antigen levels of uPA, PAI-1 and cathepsin D were immunoenzymatically determined in tumour tissue extracts. SPF and ploidy were determined flow-cytometrically, Ki‴-67, p53, and HER-2/neu immunohistochemically in adjacent paraffin sections. Their prognostic impact on disease-free (DFS) and overall survival (OS) was compared to that of traditional factors (tumour size, grading, hormone receptor status). Univariate analysis determined PAI-1 (P < 0.001), uPA (P = 0.008), cathepsin D (P = 0.004) and SPF (P = 0.023) as significant for DFS. All other factors failed to be of significant prognostic value. In a Cox model, only PAI-1 was significant for DFS (P < 0.001, relative risk (RR) 6.2). In CART analysis for DFS, the combination of PAI-1 and uPA gave the best risk group discrimination. For OS, PAI-1, cathepsin D, tumour size and ploidy were statistically significant in univariate, but PAI-1 was the only independently significant factor in Cox analysis (P < 0.001, RR 8.9). In particular, this analysis shows that PAI-1 is still a strong and independent prognostic factor in node-negative breast cancer after extended 6-year median follow-up. © 1999 Cancer Research Campaign
format Text
id pubmed-2362313
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23623132009-09-10 Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up Harbeck, N Dettmar, P Thomssen, C Berger, U Ulm, K Kates, R Höfler, H Jänicke, F Graeff, H Schmitt, M Br J Cancer Regular Article Factors reflecting two major aspects of tumour biology, invasion (urokinase-type plasminogen activator (uPA), plasminogen activator inhibiter (PAI-1), cathepsin D) and proliferation (S-phase fraction (SPF), Ki-67, p53, HER-2/neu), were assessed in 125 node-negative breast cancer patients without adjuvant systemic therapy. Median follow-up time was 76 months. Antigen levels of uPA, PAI-1 and cathepsin D were immunoenzymatically determined in tumour tissue extracts. SPF and ploidy were determined flow-cytometrically, Ki‴-67, p53, and HER-2/neu immunohistochemically in adjacent paraffin sections. Their prognostic impact on disease-free (DFS) and overall survival (OS) was compared to that of traditional factors (tumour size, grading, hormone receptor status). Univariate analysis determined PAI-1 (P < 0.001), uPA (P = 0.008), cathepsin D (P = 0.004) and SPF (P = 0.023) as significant for DFS. All other factors failed to be of significant prognostic value. In a Cox model, only PAI-1 was significant for DFS (P < 0.001, relative risk (RR) 6.2). In CART analysis for DFS, the combination of PAI-1 and uPA gave the best risk group discrimination. For OS, PAI-1, cathepsin D, tumour size and ploidy were statistically significant in univariate, but PAI-1 was the only independently significant factor in Cox analysis (P < 0.001, RR 8.9). In particular, this analysis shows that PAI-1 is still a strong and independent prognostic factor in node-negative breast cancer after extended 6-year median follow-up. © 1999 Cancer Research Campaign Nature Publishing Group 1999-05 1999-05-01 /pmc/articles/PMC2362313/ /pubmed/10408848 http://dx.doi.org/10.1038/sj.bjc.6690373 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Harbeck, N
Dettmar, P
Thomssen, C
Berger, U
Ulm, K
Kates, R
Höfler, H
Jänicke, F
Graeff, H
Schmitt, M
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
title Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
title_full Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
title_fullStr Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
title_full_unstemmed Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
title_short Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
title_sort risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362313/
https://www.ncbi.nlm.nih.gov/pubmed/10408848
http://dx.doi.org/10.1038/sj.bjc.6690373
work_keys_str_mv AT harbeckn riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT dettmarp riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT thomssenc riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT bergeru riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT ulmk riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT katesr riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT hoflerh riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT janickef riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT graeffh riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup
AT schmittm riskgroupdiscriminationinnodenegativebreastcancerusinginvasionandproliferationmarkers6yearmedianfollowup